Étiquette : neurobiologie

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders, Francisco Navarrete et al., 2021

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares and Jorge Manzanares Frontiers in Pharmacology, 2021, 12, Article 696010, 1-24. Doi : 10.3389/fphar.2021.626010   Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s, or [...]

Lire la suite

Involvement of the endocannabinoid system in drug addiction, Rafael Maldonado et al., 2006

Involvement of the endocannabinoid system in drug addiction, Rafael Maldonado, Olga Valverde and Fernando Berrendero Trends in Neurosciences, 2006, 29, (4), 225-232. Doi : 10.1016/j.tins.2006.01.008   Recent studies have shown that the endocannabinoid system is involved in the common neurobiological mechanism underlying drug addiction. This system participates in the primary rewarding effects of cannabinoids, nicotine, alcohol and opioids, through the release of endocannabinoids in the ventral tegmental area. Endocannabinoids are also involved in the motivation to seek drugs by a dopamine-independent mechanism, demonstrated for psychostimulants and opioids. The endocannabinoid system also participates in the common mechanisms underlying relapse to drugseeking behaviour by mediating the motivational effects [...]

Lire la suite

Association of Cannabis Use During Adolescence With Neurodevelopment, Matthew D. Albaugh et al., 2021

Association of Cannabis Use During Adolescence With Neurodevelopment Matthew D. Albaugh, PhD; Jonatan Ottino-Gonzalez, PhD; Amanda Sidwell, BS; Claude Lepage, PhD; Anthony Juliano, PsyD; Max M. Owens, PhD; Bader Chaarani, PhD; Philip Spechler, PhD; Nicholas Fontaine, BS; Pierre Rioux, MSc; Lindsay Lewis, PhD; Seun Jeon, PhD; Alan Evans, PhD; Deepak D’Souza, MD; Rajiv Radhakrishnan, MD; Tobias Banaschewski, MD, PhD; Arun L.W. Bokde, PhD; Erin Burke Quinlan, PhD; Patricia Conrod, PhD; Sylvane Desrivières, PhD; Herta Flor, PhD; Antoine Grigis, PhD; Penny Gowland, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot,MD, PhD; Marie-Laure Paillère Martinot,MD, PhD; Frauke Nees, PhD; Dimitri Papadopoulos [...]

Lire la suite

Ayahuasca : Uses, Phytochemical and Biological Activities, Edgar Antonio Estrella‑Parra et al., 2019

Ayahuasca : Uses, Phytochemical and Biological Activities Edgar Antonio Estrella‑Parra · Julio Cesar Almanza‑Pérez · Francisco Javier Alarcón‑Aguilar Natural Products and Bioprospecting, 2019, 9, 251–265 doi : 10.1007/s13659-019-0210-5   Abstract Ayahuasca (caapi, yajé), is a psychoactive brew from the Amazon Basin region of South America traditionally considered a “master plant.” It is prepared as a decoction from Banisteriopsis caapi and Psychotria viridis, which it is thought that it stimulates creative thinking and visual creativity. Native healers of the Orinoco and Amazon basins have used traditionally ayahuasca as a healing tool for multiple purposes, particularly to treat psychological disorders in the patients, with some beneficial effects experimentally [...]

Lire la suite

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale, Dr Christian SUEUR, GRECC, septembre 2020.

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale   Dr Christian SUEUR, GRECC, septembre 2020.     Psychédéliques : neurobiologie et psychopharmacologie : 1 - 3 Psychédéliques et réactions indésirables : 4 - 5 Psychédéliques et psychopathologie : 6 - 7 Psychédéliques et « psychoses induites » : 8 - 9 Psychédéliques et “Flash Backs” (Hallucinogen-Persisting Perception Disorders) : 10 - 11 Psychédéliques et « Bad trip » : 11 Psychédéliques et Réduction des risques : 12  

Lire la suite

Bibliographie : Cannabis et Cannabinoïdes en Neurologie, Docteur Christian SUEUR, GRECC, avril 2020

Bibliographie Cannabis et Cannabinoïdes en Neurologie   Docteur Christian SUEUR, GRECC, avril 2020.     Cannabinoïdes et Sclérose en Plaque, p 4. Cannabinoïdes et Migraines, p 7. Cannabinoïdes et maladies neurodégénératives, p 8. Cannabinoïdes et Maladie de Parkinson, p 10. Cannabinoïdes et Maladie de Huntington, p 11. Cannabinoïdes et Maladie d’Alzheimer, p 12.    

Lire la suite

A dangerous method ? Psychedelic therapy at Modum Bad, Norway, 1961–76, Petter Grahl Johnstad, 2020

A dangerous method ? Psychedelic therapy at Modum Bad, Norway, 1961–76 Petter Grahl Johnstad History of Psychiatry, 2020, 1–10 Doi : 10.1177/0957154X19894537   Abstract After many years of disregard, the use of psychedelic drugs in psychiatric treatment has re-emerged in recent years. The prospect that psychedelics may again be integrated into mainstream psychiatry has aroused interest in long-forgotten research and experience from the previous phase of psychedelic therapy, which lasted from the late 1940s to the 1970s. This article will discuss one large-scale psychedelic therapy programme at Modum Bad Nervesanatorium, a psychiatric clinic which treated 379 inpatients with psychedelic drugs during the years 1961–76. The psychiatrists [...]

Lire la suite

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans, José Carlos Bouso et al., 2015

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans José Carlos Bouso, FernandaPalhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba European Neuropsychopharmacology, 2015, 25, 483–492 http://dx.doi.org/10.1016/j.euroneuro.2015.01.008 Abstract Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception,emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that psychedelic 5-hydroxytryptamine (5HT)2A [...]

Lire la suite